<DOC>
	<DOCNO>NCT00781430</DOCNO>
	<brief_summary>The purpose study ass pharmacokinetics neratinib assess safety tolerability neratinib healthy subject subject chronic liver disease .</brief_summary>
	<brief_title>Study Evaluating The PK And Safety Of Neratinib In Healthy Subjects And Subjects With Chronic Liver Disease</brief_title>
	<detailed_description />
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<criteria>Men woman nonchildbearing potential ( WONCBP ) age 18 65 year inclusive screening . WONCBP may include either surgically sterile ( hysterectomy oophorectomy ) postmenopausal =1 year ( folliclestimulating hormone [ FSH ] level =38 mIU/mL ) must negative serum pregnancy test result within 48 hour administration test article . 2Nonsmoker smoker few 10 cigarette per day determine history . Must able abstain smoking inpatient stay . 3Have high probability compliance completion study Family history QT prolongation , syncope , seizure , unexplained cardiacrelated death . 2Presence history disorder may prevent successful completion study . 3History drug abuse within 1 year study day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>